ANZCA Primary
Physiology
Haematology
High Evidence

Coagulation and Haemostasis

Haemostasis maintains blood fluidity while preventing bleeding through vascular, platelet, and coagulation factors working in concert. Primary haemostasis: Vascular spasm, platelet adhesion (glycoprotein Ib-von...

Updated 2 Feb 2026
1 min read
Citations
84 cited sources
Quality score
54 (gold)

Clinical board

A visual summary of the highest-yield teaching signals on this page.

Urgent signals

Safety-critical features pulled from the topic metadata.

  • DIC with bleeding and thrombosis
  • Massive transfusion with coagulopathy
  • Thrombocytopenia <50 × 10⁹/L with bleeding
  • INR >1.5 or APTT >45 seconds

Exam focus

Current exam surfaces linked to this topic.

  • ANZCA Primary Written
  • ANZCA Primary Viva

Editorial and exam context

ANZCA Primary Written
ANZCA Primary Viva
Clinical reference article

Quick Answer

Haemostasis maintains blood fluidity while preventing bleeding through vascular, platelet, and coagulation factors working in concert. Primary haemostasis: Vascular spasm, platelet adhesion (glycoprotein Ib-von Willebrand factor interaction), activation (shape change, granule release), aggregation (GPIIb/IIIa-fibrinogen bridges) forming platelet plug. Secondary haemostasis: Coagulation cascade with amplification via positive feedback loops. Extrinsic pathway (PT/INR): Factor VIIa + Tissue Factor (TF) activate Factor X; Intrinsic pathway (APTT): Contact activation (XII → XI → IX + VIII) activates Factor X; Common pathway: Factor Xa + Va + Ca²⁺ + phospholipid (prothrombinase complex) converts prothrombin (II) to thrombin (IIa); thrombin converts fibrinogen (I) to fibrin (Ia) and activates XIII (cross-links fibrin). Regulation: Antithrombin (inhibits thrombin, Xa, IXa, XIa), Protein C/S (inactivate Va and VIIIa), Tissue Factor Pathway Inhibitor (TFPI inhibits VIIa-TF complex). Fibrinolysis: Plasminogen → plasmin (tPA, urokinase) degrades fibrin; regulated by PAI-1 and α2-antiplasmin. Anaesthetic implications: Coagulopathy from dilution (massive transfusion), consumption (DIC), hypothermia, acidosis (lethal triad); thrombocytopenia (TACO, HIT, ITP); drug effects (heparin, warfarin, DOACs). Viscoelastic testing (TEG/ROTEM): Rapid assessment of clot formation, strength, and fibrinolysis; guides goal-directed therapy. Indigenous populations have higher rates of thromboembolism and may have different clotting factor concentrations requiring careful thromboprophylaxis. [1-10]